Study: Lower Dosage Carnipure Supplementation May Have Effects on Weight Management

water weightcrop.jpg

27 Feb 2013 --- During the four-weeks study, 24 overweight adults were split into 4 groups: group A received a daily Carnipure supplement (500 mg L-carnitine), group B received the Carnipure supplement combined with motivation training, group C received placebo and group D placebo plus motivation training.

--- A new study confirmed the role of Carnipure (l-carnitine from supplier Lonza) supplementation combined with healthy lifestyle education on the success of weight management programs. The primary objective of this pilot, double-blind, randomized, placebocontrolled clinical trial conducted by the Japanese Clinical Research Organization Souken was to examine the effect of Carnipure tartrate providing a low dose of L-carnitine on weight management and energy metabolism-related parameters in overweight but healthy human subjects.

During the four-weeks study, 24 overweight adults were split into 4 groups: group A received a daily Carnipure supplement (500 mg L-carnitine), group B received the Carnipure supplement combined with motivation training, group C received placebo and group D placebo plus motivation training. Motivation training included a 30 minute face-to-face session with the study investigator, as well as a 15 minute session 2 weeks into the study, in which subjects received detailed information about the metabolic function of L-carnitine as well as the impact of lifestyle changes with regard to metabolic diseases. They were also instructed to increase their daily activity, use a step counter, reduce calorie intake and use a food diary while monitoring their body weight on a daily basis.

Only subjects in group B, who received the combination of Carnipure and motivation training, showed a statistically significant reduction in body weight after the four week supplementation period, while there were no significant changes in body weight in any of the other groups. In addition, group B also showed the largest decrease in blood triglyceride levels among all the groups. Until now, the majority of clinical trials have used higher daily doses of L-carnitine for various reasons. This is the first study showing an effect of a daily 500 mg L-carnitine supplement on body weight.

It is well-known that caloric intake alone does not determine an individual’s body weight. Many other factors also play a role, first and foremost the level of physical activity as the main consumer of energy. There is no magic bullet among available food supplements on the market that can decrease body weight considerably without additional alterations to diet and exercise routines. “Although this pilot trial involved only a small number of people per group, the results are significant. Carnipur supplementation in combination with lifestyle changes can help decrease body weight”, comments Mike DeGennaro, Global Head Human Nutrition at Lonza. Carnipure is high quality L-carnitine, a nutrient essential for energy metabolism. Its primary role is the transport of long-chain fatty acids into the mitochondria where they are broken down to generate energy. Decreasing fat mass while preserving muscle mass is the goal of long  term, sustained weight management. To decrease fat mass, fat stores must be broken down and used for energy. Independent trials have confirmed that Carnipure™ supplementation can increase this process.

Data are published in the February issue of Food and Nutrition Sciences (Vol 4, No 2), and can be found at the following URL:

To contact our editorial team please email us at



Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment. 

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. 

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources. 

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Related Articles

Health & Nutrition News

Has the haze lifted? As cannabis-derivatives get the green light, NPD expansion is set to grow

15 Jan 2019 --- Cannabis-derivatives, such as hemp and cannabidiol (CBD), have been increasingly cropping up on ingredients lists in the US and elsewhere. A recent ruling, which came as the US Government launched its farm bill in December 2018, alleviates hemp of its illegal status, which is expected to spur further innovation. Part one of this NutritionInsight two-part report into cannabis-derived products in the nutrition and food industry explored the softening regulatory environment. Part two considers how the industry may respond to the opportunities that such regulation shifts may bring to the US and Canada, for example.

Health & Nutrition News

Lonza to establish strategic biomanufacturing base in China

10 Dec 2018 --- GE Healthcare is to develop a biologics facility for Lonza in Guangzhou, China, as part of a recently inked agreement. The facility is part of a larger biomanufacturing initiative between GE Healthcare and Guangzhou Development District (GDD). For the project to progress, Lonza will sign a memorandum of understanding with GDD. The new facility will give Lonza Pharma & Biotech a strategic base in China to respond to growing demand for high-quality CDMO services in the country.

Health & Nutrition News

Weekly Roundup: DSM enters Japanese partnership on healthy aging, Croda expands with Marine Biotechnology innovation center

16 Nov 2018 --- In nutrition news this week, Croda opened a new Center of Innovation for Marine Biotechnology and DSM entered a collaboration on the development of services in nutritional rehabilitation and disease prevention in Japan. Lonza and Sartorius Stedim Biotech (SSB) are modifying their current agreement for the supply of cell culture media by mutual accord. Lastly, Gelita recently hosted a US symposium called, “The Sounds of Health and Nutrition,” which aimed to offer inspiration for market opportunities in the global health and nutrition marketplace.

Health & Nutrition News

Lonza divests water business in US$630m deal to focus on growth of healthcare business

01 Nov 2018 --- Lonza has sold its Water Care business to Platinum Equity in a US$630 million deal. The move allows Lonza to focus on its healthcare continuum strategy, which includes patient healthcare, consumer preventive healthcare and consumer's healthy environment. The company posted strong Q3 results last week across the Healthcare Continuum. In the first half of this year, Lonza reported strong momentum with organic growth of 8 percent (like-for-like) sales and 11 percent CORE EBITDA. The company’s businesses along the healthcare continuum achieved double-digit organic sales growth.  

Health & Nutrition News

Lonza reports strong momentum for Q3 boosted by businesses along the healthcare continuum

25 Oct 2018 --- Lonza has reported ongoing momentum in the third quarter (Q3), boosted by its businesses along the healthcare continuum, including Pharma & Biotech and Speciality Ingredients. The company reports it is capitalizing on organic growth opportunities such as its Ibex solutions, which it recently expanded.

More Articles